Melane Sampson, Author at BioTuesdays

Feature

Bridging clinical trial diversity gaps and accelerating R&D in rare disease

As founder and executive chair of the non-profit Indo-US Organization for Rare Disease (IndoUSrare), Harsha Rajasimha, Ph.D., social entrepreneur, and subject matter expert in bioinformatics, data analysis, and...

December 12, 2023

Feature

Upswing Health harmonizes human touch with AI-driven technology to assess MSK pain

Closely held Upswing Health, a virtual orthopedic company, is reinventing orthopedic care delivery through its virtual orthopedic musculoskeletal symptom assessment tool and customized pain management program...

November 21, 2023

Feature

Hygieia – leveraging science + research + technology to revolutionize how patients manage insulin dosing

Closely held Hygieia, a digital therapeutics company for insulin therapy, is reforming how physicians and people with type 2 diabetes manage insulin with its breakthrough proprietary mobile app, d-Nav, which...

October 24, 2023

Feature

EndoGlow – advancing fluorescent-guided surgeries with breakthrough device and technology

Closely held EndoGlow, a medical device company, is revolutionizing minimally invasive surgery and improving patient outcomes by enhancing visualization through its proprietary Tissue Reveal Technology (TRT), a polymer...

October 10, 2023

Executive Moves

Zymeworks names Paul Moore as CSO

Zymeworks (NYSE:ZYME) is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as chief scientific officer, reporting directly to the CEO, effective July 18. Dr. Moore brings more than 25...

June 28, 2022

Executive Moves

Hepion adds accomplished biopharmaceutical executives Anand Reddi and Dr. Kaouthar Lbiati to board

Anand Reddi, M.S. Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its board of directors, effective immediately. “Mr. Reddi and Dr. Lbiati have a remarkable wealth...

June 28, 2022

Developments

LENSAR receives FDA clearance of ALLY Adaptive Cataract Treatment System

The FDA cleared LENSAR’s (NASDAQ:LNSR) next-generation ALLY Adaptive Cataract Treatment System to enable cataract surgeons to complete the femtosecond-laser-assisted cataract surgery procedure seamlessly in a single...

June 13, 2022

Developments

Tonix Pharma TNX-1500 data presented at American Transplant Congress

Faculty at the Center for Transplantation Sciences, Massachusetts General Hospital, presented data at the 2022 American Transplant Congress about Tonix Pharmaceuticals’ (NASDAQ:TNXP) TNX-1500 product candidate in...

June 9, 2022

Developments

PharmaJet sponsor study published in The Lancet

A Phase 3 clinical study sponsored by PharmaJet’s partner, Zydus Lifesciences, featuring ZyCoV-D, the world’s first plasmid-DNA vaccine approved for use in humans and delivered by the PharmaJet Tropis Intradermal needle...

June 8, 2022

Developments

Qualigen acquires majority stake in NanoSynex

Qualigen Therapeutics (NASDAQ:QLGN) completed the acquisition of a majority stake in NanoSynex, an Israeli-based developer of next generation diagnostics technology. In a statement, Michael Poirier, chairman and CEO of...

June 2, 2022

Author - Melane Sampson

Bridging clinical trial diversity gaps and accelerating R&D in rare disease

Upswing Health harmonizes human touch with AI-driven technology to assess MSK pain

Hygieia – leveraging science + research + technology to revolutionize how patients manage insulin dosing

EndoGlow – advancing fluorescent-guided surgeries with breakthrough device and technology

Zymeworks names Paul Moore as CSO

Hepion adds accomplished biopharmaceutical executives Anand Reddi and Dr. Kaouthar Lbiati to board

LENSAR receives FDA clearance of ALLY Adaptive Cataract Treatment System

Tonix Pharma TNX-1500 data presented at American Transplant Congress

PharmaJet sponsor study published in The Lancet

Qualigen acquires majority stake in NanoSynex

Subscribe